Clinical Trial Update: A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of cabozantinib and atezolizumab for advanced/metastatic non-small cell lung cancer; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Jun Zhang, MD, PhD | Conditions: Lung Cancer, NSCLC Stage IV | Phase 2 | Status: NOT_YET_RECRUITING